

MeRo/04/Neb-LVD/001

Effects of Nebivolol on Subclinical left ventricular dysfunction. A comparative study against Metoprolol (ENESYS Study)

This study has completed the enrolment of patients

Sponsor: Berlin Chemie AG

Intervention: Nebivolol 5 mg, tablets, once daily

Metoprolol 50 mg, b.i.d. In addition to both treatments, HCTZ will be administered from the beginning once daily in order to achieve consistent control of blood pressure during the treatment period

Condition: hypertension, left ventricular hypertrophy

This study is designed to compare the activity of Nebivolol vs Metoprolol in the changes of:

- longitudinal myocardial velocities at rest (assessed by tissue Doppler echocardiography)
- systolic functional reserve (calculated as the absolute and relative increase of the myocardial systolic velocities at peak stress from rest)
- Brain Natriuretic Peptide (BNP, NT-proBNP) after 6 months of treatment with the two treatments

Study type & design: randomized, parallel group, active-controlled, open label study

Main criteria for inclusion:

Patients with a history of primary hypertension Age >18 yrs With a daytime ambulatory blood pressure >140 mmHg and/or >90 mmHg With left ventricular hypertrophy In sinus rhythm

Main criteria for exclusion:

Severe arterial hypertension (SBP>180 mm Hg and/or DBP>110 mm Hg)
Any history of coronary heart disease Any history of cerebrovascular disease Renal impairment